Comparing Continuous Glucose Monitoring and Blood Glucose Monitoring in Adults With Inadequately Controlled, Insulin-Treated Type 2 Diabetes (Steno2tech Study): A 12-Month, Single-Center, Randomized Controlled Trial
Primary result · TIR 3.9-10.0 mmol/LResult — go to the resultBetween-group difference 15.2 % 95% CI 4.6–25.9Authors' conclusion
In adults with inadequately controlled insulin-treated type 2 diabetes, the 12-month impact of CGM was superior to BGM in improving glucose control and other crucial health parameters. The findings support the use of CGM in the insulin-treated subgroup of type 2 diabetes.
Study context
- Population
- Adults ≥18 years with inadequately controlled, insulin-treated T2D (HbA1c ≥7.5% [58 mmol/mol]), outpatient clinic at Steno Diabetes Center Copenhagen, Denmark; median baseline HbA1c 8.3 (7.8, 9.1)%, 61.8% malerandomized 1:1
- Participants
- 76 adults
- Comparison
- Continuous glucose monitoring (CGM) vs blood glucose monitoring (BGM) for 12 months
- Primary endpoint
- Between-group difference in change in time in range (TIR) 3.9-10.0 mmol/L, assessed by blinded CGM
- Follow-up
- Baseline, 6 and 12 months
Methodological detailssingle-center, parallel, open-label, All participants received a diabetes self-management education course and were followed by usual health care providers
- Single-center
- Parallel
- Open-label
- All participants received a diabetes self-management education course and were followed by usual health care providers
Primary result
TIR 3.9-10.0 mmol/L · 12 months
Between-group difference
15.2 %
95% CI 4.6–25.9
CGMvs BGM
between-group difference 15.2 % (95% CI 4.6–25.9)
As reported in the abstract
Secondary outcomes
| Outcome | Between-group difference (%) (CI) | |
|---|---|---|
| HbA1c · 12 months−9.4 mmol/mol (−15.2; −3.5) | −0.9 (−1.4 to −0.3) | |
| −2−101Difference, % (linear scale) |
| Outcome | Between-group difference (units/day) (CI) | |
|---|---|---|
| Total daily insulin dose · 12 months | −10.6 (−19.9 to −1.3) | |
| −20−10010Difference, units/day (linear scale) |
| Outcome | Between-group difference (kg) (CI) | |
|---|---|---|
| Weight · 12 months | −3.3 (−5.5 to −1.1) | |
| −10−505Difference, kg (linear scale) |
| Outcome | Between-group difference (kg/m²) (CI) | |
|---|---|---|
| BMI · 12 months | −1.1 (−1.8 to −0.3) | |
| −2−101Difference, kg/m² (linear scale) |
Participant-reported outcomes · 12 months
- Greater self-rated diabetes-related health, well-being, satisfaction and health behavior with CGM vs BGM
Original publication
Comparing Continuous Glucose Monitoring and Blood Glucose Monitoring in Adults With Inadequately Controlled, Insulin-Treated Type 2 Diabetes (Steno2tech Study): A 12-Month, Single-Center, Randomized Controlled Trial. Diabetes Care. Published 15 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →